Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know

Zacks02-05 00:47

Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2509460276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-05 00:47","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2509460276","market":"us","top_or_hot":-1,"title":"Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know","media":"Zacks","content":"<div>\n<p>Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is ...</p>\n\n<a href=\"https://finance.yahoo.com/news/incyte-gears-report-q4-earnings-164700849.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Gears Up to Report Q4 Earnings: Here's What You Should Know\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-05 00:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/incyte-gears-report-q4-earnings-164700849.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is ...</p>\n\n<a href=\"https://finance.yahoo.com/news/incyte-gears-report-q4-earnings-164700849.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/incyte-gears-report-q4-earnings-164700849.html","article_id":"2509460276","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509460276","pubTimestamp":1738687620,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.15 billion, while the same for earnings is pinned at $1.58 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the past year, shares of Incyte have rallied 27.1% against the industry’s decline of 9.9%.Incyte primarily derives product revenues from the sales of its lead drug, Jakafi , in the United States and other marketed drugs.The Zacks Consensus Estimate for Jakafi's fourth-quarter sales is pegged at $745 million.Incyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets.While Incyte markets Jakafi in the United States, Novartis markets the same drug as Jakavi outside the United States. INCY is expected to have received higher royalties from NVS in the to-be-reported quarter on higher J","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Incyte准备报告第四季度收益：以下是您应该了解的内容","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1,"NVS":0.9},"content_text":"Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.15 billion, while the same for earnings is pinned at $1.58 per share.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nIn the past year, shares of Incyte have rallied 27.1% against the industry’s decline of 9.9%.\nImage Source: Zacks Investment Research\nLet’s see how things might have shaped up prior to the announcement.\nFactors Likely to Influence INCY’s Q4 Results\nIncyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States and other marketed drugs.\nIts momentum is likely to have continued on the back of Jakafi, a first-in-class JAK1/JAK2 inhibitor, in all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]).\nHowever, competition from other approved drugs might have restricted sales growth potential to some extent.\nThe Zacks Consensus Estimate for Jakafi's fourth-quarter sales is pegged at $745 million.\nIncyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets.\nWhile Incyte markets Jakafi in the United States, Novartis markets the same drug as Jakavi outside the United States. INCY is expected to have received higher royalties from NVS in the to-be-reported quarter on higher Jakavi sales.\nNovartis reported strong performance of Jakavi in the fourth quarter, with sales of the drug witnessing a 13% increase on a constant currency basis. Hence, royalties from the same are likely to have been higher.\nIncyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. NVS has exclusive worldwide development and commercialization rights to Tabrecta.\nSales of Opzelura boosted Incyte’s top line in the last reported quarter. Growth in Opzelura sales is likely to have been driven by factors like increasing patient demand, refills and expansion in payer coverage (in both the indications of atopic dermatitis and vitiligo) during the fourth quarter.\nThe Zacks Consensus Estimate for Opzelura’s fourth-quarter sales is pegged at $148 million.\nWhile Jakafi’s sales and royalties are the key catalysts for INCY’s revenue growth, sales of other drugs like Minjuvi, Pemazyre, Iclusig and Olumiant’s royalties from Eli Lilly are also likely to have contributed to Incyte’s top line.\nIn February 2024, INCY entered into an asset purchase agreement with MorphoSys AG. This gave Incyte exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the United States (as Monjuvi) and outside the country (as Minjuvi).\nThe Zacks Consensus Estimate for Iclusig, Minjuvi and Pemazyre’s fourth-quarter sales is pegged at $29.69 million, $33.75 million and $22.54 million, respectively.\nIncremental sales from Zynyz, too, are expected to have boosted Incyte’s revenues in the to-be-reported quarter.\nAt the recently held J.P. Morgan Healthcare Conference, management highlighted that 2025 will be a transformational year for INCY with some potential launches.\nIncyte and partner Syndax Pharmaceuticals obtained FDA approval for axatilimab-csfr, an anti-CSF-1R antibody, for the treatment of GVHD after the failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. The candidate was approved under the brand name Niktimvo. The drug is Incyte’s second approved treatment for chronic GVHD (third-line) and will be launched soon. Investors will be keen to get an update on the launch activities for Niktimvo during the earnings announcement.\nHigher research and development expenses, as well as increased selling and general and administrative costs, are likely to have escalated operating expenses in the fourth quarter.\nEarnings Surprise History\nIncyte has a disappointing history of earnings surprises. The company missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 94.37%. In the last reported quarter, INCY posted a negative earnings surprise of 4.46%.\n\nIncyte Corporation Price and EPS Surprise\n  \nIncyte Corporation price-eps-surprise | Incyte Corporation Quote\n\nEarnings Whispers\nOur proven model does not conclusively predict an earnings beat for INCY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.\nEarnings ESP: Incyte’s Earnings ESP is -18.53% as the Most Accurate Estimate currently stands at $1.29 and the Zacks Consensus Estimate is pegged at $1.58. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.\nZacks Rank: INCY has a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nStocks to Consider\nHere are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.\nMirum Pharmaceuticals, Inc. MIRM has an Earnings ESP of +16.08% and a Zacks Rank #1 at present.\nShares of MIRM have surged 85% in the past year. MIRM beat on earnings in one of the trailing four quarters while missing the same in the remaining three occasions, delivering an average negative surprise of 26.03%.\nExelixis, Inc. EXEL has an Earnings ESP of +5.90% and a Zacks Rank #2 at present.\nShares of EXEL have gained 53.7% in the past year. Earnings of Exelixis beat estimates in three of the trailing four quarters and missed the same once, delivering an average surprise of 26.52%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovartis AG (NVS) : Free Stock Analysis Report\nIncyte Corporation (INCY) : Free Stock Analysis Report\nExelixis, Inc. (EXEL) : Free Stock Analysis Report\nMirum Pharmaceuticals, Inc. (MIRM) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2509460276"}